CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.601
-0.027 (-4.30%)
Nov 21, 2024, 11:37 AM EST - Market open

Company Description

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.

The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.

In addition, the company’s product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease.

CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI Corporation
CEL-SCI logo
Country United States
Founded 1983
IPO Date Jan 1, 1987
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Geert Kersten

Contact Details

Address:
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
United States
Phone 703 506 9460
Website cel-sci.com

Stock Details

Ticker Symbol CVM
Exchange NYSEAMERICAN
Fiscal Year October - September
Reporting Currency USD
CIK Code 0000725363
CUSIP Number 150837607
ISIN Number US1508376076
Employer ID 84-0916344
SIC Code 2836

Key Executives

Name Position
Geert R. Kersten Esq. Chief Executive and Financial Officer, Treasurer and Director
Patricia B. Prichep Senior Vice President of Operations and Corporate Secretary
Dr. Eyal Talor Ph.D. Chief Scientific Officer
Dr. Daniel H. Zimmerman Ph.D. Senior Vice President of Research and Cellular Immunology
John Cipriano Senior Vice President of Regulatory Affairs
Dr. Giovanni Selvaggi M.D. Acting Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 15, 2024 8-K Current Report
Nov 13, 2024 8-K Current Report
Nov 7, 2024 EFFECT Notice of Effectiveness
Oct 30, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
Oct 25, 2024 S-3 Registration statement under Securities Act of 1933
Oct 11, 2024 POS AM Post-Effective amendments for registration statement
Oct 10, 2024 AW Amendment Withdrawal Request
Oct 8, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
Sep 17, 2024 8-K Current Report
Aug 30, 2024 S-8 Securities to be offered to employees in employee benefit plans